1 | GLP-1 drugs are transforming obesity care – but the gut pays a price
Once-weekly GLP-1 receptor agonists such as semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) routinely deliver 10 – 20 % body-weight reduction and substantial cardiometabolic benefits (1).
The flip side is tolerability: gastrointestinal (GI) complaints such as nausea, vomiting, constipation, diarrhoea, bloating are by far the commonest adverse events (2).
Across trials and real-world reports, up to 83 % of users experience at least one GI side-effect and many stop therapy early .
2 | Why GLP-1 therapy disturbs the microbiome
Rapid weight loss, altered eating patterns and slowed gastric emptying all reshape the intestinal ecosystem. Studies show shifts in beneficial taxa (e.g. Akkermansia) alongside a drop in overall microbial diversity, which can blunt metabolic gains and prolong discomfort (3).
Supporting the microbiome while the drug remodels gut physiology therefore becomes a clinical priority, both to enhance efficacy and to keep patients on treatment (3,4).
3 | Forte80™ – targeted microbiome support designed for GLP-1 users
Azento Health formulated Forte80™ to tackle exactly those pain points. Each two-capsule daily serving delivers 80 billion CFU across four patent-deposited strains (3):
| Strain | Daily CFU | Key role for GLP-1 patients* |
| Bifidobacterium lactis AZHx1 | 45 bn | Relieves constipation, supports gut barrier, aids glucose & lipid control |
| Lactobacillus reuteri AZHx2 | 5 bn | Modulates gut motility → less nausea/fullness |
| Lactobacillus casei AZHx3 | 15 bn | Anti-inflammatory, counters bloating/gas |
| Lactobacillus rhamnosus GG | 15 bn | Proven anti-diarrhoeal, immune modulation |
*Mechanisms summarised from Azento Health science brief (3).
A single daily dose is roughly equivalent to eating 80 pots of bifidus yoghurt but with clinically selected strains protected by cryo-technology to survive the stomach and reach the intestine alive (3,1).
4 | What users can expect – a phased timeline
Clinical rationale from Azento Health’s treatment-pathway model suggests (3):
- Days 1 – 7: early improvements in comfort; gas may transiently increase as the microbiome adjusts.
- Week 2 – 4: meaningful relief of constipation/diarrhoea; nausea often eases.
- Month 1 – 3: strengthened gut barrier, lower inflammation, steadier motility → substantial drop in GLP-1 side-effects.
- Beyond 12 weeks: sustained microbiome balance that may even potentiate weight-loss efficacy and metabolic markers.
For maximal benefit Azento Health advises starting Forte80™ 2-4 weeks before the first GLP-1 injection (or as soon as GI issues appear) and continuing daily (1).
5 | Real-world signals
Shop-site reviews collected in 2025 echo the science: many users report “less nausea,” “regular bowels,” and “feeling normal again” within the first fortnight while staying on semaglutide or tirzepatide (1). Although anecdotal, this aligns with published probiotic data showing improved adherence when GI distress is mitigated (5).
6 | Practical checklist for clinicians and patients
- Screen for baseline GI history and microbiome-sensitive comorbidities.
- Initiate Forte80™ (2 caps/day, preferably morning, no refrigeration needed).
- Educate about transient gas/adjustment phase and importance of consistency.
- Layer lifestyle: fibre-rich diet, hydration, low-irritant foods, gentle activity.
- Review at 4, 12 weeks; titrate GLP-1 dose if side-effects persist.
7 | Take-home
GLP-1 agonists unlock unprecedented weight-loss potential, yet GI intolerance remains the leading cause of drop-out. The emerging evidence base summarised by Azento Health and encapsulated in Forte80™—shows that targeted probiotic therapy can stabilise the microbiome, cut side-effects and let patients stay the course. In the era of GLP-1-driven obesity care, gut-focused support isn’t an optional add-on; it’s fast becoming standard of care for durable success.
Source: This article integrates data from Azento Health/Forte80™, peer-reviewed literature, and the “Adipositas” information sheet supplied by the author.
Medical disclaimer: Forte80™ is a food supplement, not a drug. Patients should consult their healthcare professional before starting any new product, especially alongside prescription GLP-1 therapy.
Read our introduction article on Immunity & Gut Health here:
